Mizugaki, H., Yamamoto, N., Murakami, H., Kenmotsu, H., Fujiwara, Y., Ishida, Y., . . . Takahashi, T. (2016). Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drugs.
Citação norma ChicagoMizugaki, Hidenori, Noboru Yamamoto, Haruyasu Murakami, Hirotsugu Kenmotsu, Yutaka Fujiwara, Yoshimasa Ishida, Tomohisa Kawakami, and Toshiaki Takahashi. "Phase I Dose-finding Study of Monotherapy With Atezolizumab, an Engineered Immunoglobulin Monoclonal Antibody Targeting PD-L1, in Japanese Patients With Advanced Solid Tumors." Invest New Drugs 2016.
Citação norma MLAMizugaki, Hidenori, et al. "Phase I Dose-finding Study of Monotherapy With Atezolizumab, an Engineered Immunoglobulin Monoclonal Antibody Targeting PD-L1, in Japanese Patients With Advanced Solid Tumors." Invest New Drugs 2016.